SEARCH

SEARCH BY CITATION

References

  • 1
    Gaydos LA, Freireich EJ, Mantel N: The Quantitative relation between platelet count and hemorrhage in patients with acute leukemia. NEJM 1962; 266:905909
  • 2
    Higby DJ, Cohen E, Holland JF, Sinks L: The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double blind study. Transfusion 1974; 14:440446
  • 3
    Solomon J, Bofenkamp T, Fahey JL, Chillar RK, Beutel E: Platelet prophylaxis in acute non-lymphoblastic leukaemia. Lancet 1978; 1:267
  • 4
    Murphy S, Litwin S, Herring LM, Koch P, Remischovsky J, Donaldson MH, Evans AE, Gardner FH: Indications for platelet transfusion in children with acute leukemia. Am J Hematol 1982; 12:347356
  • 5
    Stanworth SJ, Hyde C, Heddle N, Rebulla P, Brunskill S, Murphy MF: Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev 2004; 4:CD004269
  • 6
    Slichter SJ, Harker LA: Thrombocytopenia: mechanisms and management of defects in platelet production. Clin Haematol 1978; 7:523539
  • 7
    Gil-Fernández JJ, Alegre A, Fernández-Villalta MJ, Pinilla I, Gómez García V, Martinez C, Tomás JF, Arranz R, Figuera A, Cámara R, Fernández-Rañada JM: Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplant 1996; 18:931935
  • 8
    Navarro JT, Hernandez JA, Ribera JM, Sancho JM, Oriol A, Pujol M, Milla F, Feliu E: Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL. Haematologica 1998; 83:9981000
  • 9
    Lawrence JB, Yomtovian RA, Hammons T, Masarik SR, Chongkolwatana V, Creger RJ, Manka A, Lazarus HM: Lowering the prophylactic platelet transfusion threshold: a prospective analysis. Leuk Lymphoma 2001; 41:6776
  • 10
    Gmur J, Burger J, Schanz U, Fehr J, Schaffner A: Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 1991; 338:12231226
  • 11
    Wandt H, Frank M, Ehninger G, Schneider C, Brack N, Daoud A, Fackler-Schwalbe I, Fischer J, Gackle R, Geer T, Harms P, Löffler B, Ohl S, Otremba B, Raab M, Schönrock-Nabulsi P, Strobel G, Winter R, Link H: Safety and cost effectiveness of a 10 × 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998; 91:36013606
  • 12
    Callow CR, Swindell R, Randall W, Chopra R: The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy. Br J Haematol 2002; 118:677682
  • 13
    Rebulla P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Tognoni G, Barbui T, Mandelli F, Sirchia G: The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. N Engl J Med 1997; 337:18701875
  • 14
    Heckman KD, Weiner GJ, Davis CS, Strauss RG, Jones MP, Burns CP: Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J Clin Oncol 1997; 15:11431149
  • 15
    Zumberg MS, Del Rosario ML, Nejame CF, Pollock BH, Garzarella L, Kao KJ, Lottenberg R, Wingard JR: A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger. Biol Blood Marrow Transplant 2002; 8:569576
  • 16
    Heddle NM, Arnold DM, Boye D, Webert KE, Resz I, Dumont LJ: Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion 2008; 48:14471458
  • 17
    Lozano M, Cid J: Consensus and controversies in platelet transfusion: trigger for indication and platelet dose. Tranfus Clin Biol 2007; 14:504508
  • 18
    Norol F, Bierling P, Roudot-Thoraval F, Le Coeur FF, Rieux C, Lavaux A, Kuentz M, Duedari N: Platelet transfusion: a dose-response study. Blood 1998; 92:14481453
  • 19
    Klumpp TR, Herman JH, Gaughan JP, Russo RR, Christman RA, Goldberg SL, Ackerman SJ, Bleecker GC, Mangan KF: Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trial. Transfusion 1999; 39:674681
  • 20
    Goodnough LT, Kuter DJ, McCullough J, Slichter SJ, DiPersio J, Romo J, Peterson R, Smith KJ, Raife T, Tomita D, Armstrong S: Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood 2001; 98:13461351
  • 21
    Tinmouth A, Tannock IF, Crump M, Tomlinson G, Brandwein J, Minden M, Sutton D: Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design. Transfusion 2004; 44:17111719
  • 22
    Sensebe L, Giraudeau B, Bardiaux L, Deconinck E, Schmidt A, Bidet ML, Leniger C, Hardy E, Babault C, Senecal D: The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study. Blood 2005; 105:862864
  • 23
    Heddle NM, Cook RJ, Tinmouth A, Kouroukis CT, Hervig T, Klapper E, Brandwein JM, Szczepiorkowski ZM, AuBuchon JP, Barty RL, Lee KA; SToP Study Investigators of the Best Collaborative: A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009; 113:15641573
  • 24
    Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S: Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362(7):600613
  • 25
    Tinmouth AT, Freedman J: Prophylactic platelet transfusions: which dose is the best dose? A review of the literature. Transfus Med Rev 2003; 17:181193
  • 26
    Cid J, Lozano M: Lower or higher doses for prophylactic platelet transfusions: results of a meta-analysis of randomized controlled trials. Transfusion 2007; 47:464470
  • 27
    Wandt H, Schaefer-Eckart K, Frank M, Birkmann J, Wilhelm M: A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37:387392
  • 28
    Wandt H, Wendelin K, Schaefer-Eckart K, Thalheimer M, Schubert MS, Conradi R, Schwerdtfeger R, Leimer L, Kaufmann M, Dölken G, Klenner AF, Schaich M, Ehninger G: A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts) 2008; 112:286
  • 29
    Wandt H, Schaefer-Eckart K, Pilz B, Thalheimer M, Ho AD, Schaich M, Kaufmann M, Aulitzky WE, Haenel M, Herbst R, Doelken G, Klenner AF, Freund M, Junghanss C, Ehninger G: Experience with a therapeutic platelet transfusion strategy in acute myeloid leukemia: preliminary results of a randomized multicenter study after enrolment of 175 patients. Blood (ASH Annual Meeting Abstracts) 2009; 114:20
  • 30
    Nevo S, Fuller AK, Zahurak ML, Hartley E, Borinsky ME, Vogelsang GB: Profound thrombocytopenia and survival of hematopoietic stem cell transplant patients without clinically significant bleeding, using prophylactic platelet transfusion triggers of 10 × 10(9) or 20 × 10(9) per L. Transfusion 2007; 47:17001709